Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jose Torregrosa-Diaz"'
Autor:
Felipe Suarez, Cindy Barbarin, Jean-Claude Chomel, Blandine Rammaert, Kévin Brunet, Jose Torregrosa-Diaz, Ewa Hainaut, Clément Lemaigre, Jean-Philippe Martellosio
Publikováno v:
Journal of Clinical Immunology
Journal of Clinical Immunology, Springer Verlag, 2022, 42 (1), pp.60-63. ⟨10.1007/s10875-021-01140-1⟩
Journal of Clinical Immunology, Springer Verlag, 2022, 42 (1), pp.60-63. ⟨10.1007/s10875-021-01140-1⟩
Chronic granulomatous disease (CGD) is an inherited immunodeficiency due to defective leukocyte NADPH responsible for recurrent infections and aberrant inflammation. Mutations in the CYBB gene are responsible for the X-linked CGD and account for appr
Autor:
Xavier Leleu, Jean-Claude Chomel, André Herbelin, Carine Motard, Stéphanie Ragot, Florence Tartarin, Anne Corby, Guillaume Denis, Jose Torregrosa-Diaz, Deborah Desmier, Thomas Systchenko, Lydia Roy, Jean-Marc Gombert, Emmanuel Fleck, Emilie Cayssials, Pilar Gallego-Hernanz, François Guilhot, Antoine Machet, Natacha Maillard
Publikováno v:
Cancer. 126:3438-3447
Background Long-term treatment-free remission (TFR) represents a new goal for chronic myeloid leukemia (CML). In clinical practice, tyrosine kinase inhibitor (TKI) dose reductions can be considered a means of preventing adverse effects and improving
Publikováno v:
CancerReferences. 127(6)
Publikováno v:
Hématologie. 22:17-18
La leucemie aigue lymphoblastique B (LALB) de l’adulte, en rechute ou refractaire (r/r) est de mauvais pronostic, avec a peine 10 % de survie globale (SG) a cinq ans avec chimiotherapie seule. La SG mediane est de 10 mois pour les patients ayant re